Dalbavancin Study Results to be Presented in Three Posters at the 53rd Annual ICAAC Meeting

CHICAGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two Phase 3 clinical trials of the company's lead product candidate, dalbavancin, will be presented in two posters at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, September 10-13, 2013. The trials were conducted via a Special Protocol Assessment based on the FDA's Draft Guidance for Developing Drugs for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Dalbavancin is under investigation for the treatment of ABSSSI caused by susceptible Gram-positive microorganisms. These data will be used to support the company's anticipated submission of a New Drug Application to the U.S. Food and Drug Administration at the end of September 2013.

In addition, R.M. Alden Research Lab will present in vitro data regarding the activity of dalbavancin against isolates obtained from osteomyelitis infections. This research was supported by a grant from Durata Therapeutics.

The following posters will be presented:

Tuesday, September 10, 2013
12 p.m. - 2 p.m.
Title: DISCOVER 1: A Randomized, Double-blind Study of Dalbavancin (DAL) compared to Vancomycin (V) (with an option to switch to Linezolid (L)) in Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Authors: H. W. Boucher¹, M. Wilcox², G. H. Talbot³, A. Das⁴, S. Puttagunta⁵, M. Dunne⁵
(¹Tufts Med. Ctr., Boston, MA, ²Leeds Teaching Hosp., Leeds, UNITED KINGDOM, ³Talbot Advisors, LLC, Anna Maria, FL, ⁴InClin, San Mateo, CA, ⁵Durata Therapeutics, Branford, CT)
Poster #: L-201

Tuesday, September 10, 2013
12 p.m. – 2 p.m.
**Title: DISCOVER 2: A Randomized, Double-Blind Study of Dalbavancin (DAL) compared to Vancomycin (V) (with an option to switch to Linezolid (L)) in Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)**

Authors: M. Wilcox¹, H. W. Boucher², G. H. Talbot³, A. F. Das⁴, S. Puttagunta⁵, M. Dunne⁵ (¹Leeds Teaching Hosp., Leeds, UNITED KINGDOM, ²Tufts Med. Ctr., Boston, MA, ³Talbot Advisors, LLC, Anna Maria, FL, ⁴InClin, San Mateo, CA, ⁵Durata Therapeutics, Branford, CT)

Poster #: L-202

### Tuesday, September 10, 2013

12 p.m. – 2 p.m.

**Title: In Vitro Activity of Dalbavancin Against Consecutive Isolates of Staphylococcus Species Recovered from Osteomyelitis Infections**

Authors: D. M. Citron, E. J. Goldstein (R.M. Alden Res. Lab., Culver City, CA)

Poster #: E-140

The abstracts are currently available on the ICAAC website at [www.icaac.org](http://www.icaac.org) and copies of the posters will be available following the ICAAC meeting at [www.duratatherapeutics.com](http://www.duratatherapeutics.com).

---

### About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients.

---

### About Durata Therapeutics, Inc.

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria.

---

### Forward-looking Statements

Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements in this press release include statements about the timing of the submission of a NDA with the FDA. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the "Risk Factors" section of our most recent quarterly report on Form 10-Q, which is on file with the SEC and is also available on our website. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

CONTACT: Investor Relations and Public Affairs Contact
Allison Wey
Durata Therapeutics
Vice President, Investor Relations and Public Affairs
(312) 219-7017
awey@duratatherapeutics.com

Media Relations Contact
Geoff Curtis
DJE Science
(312) 233-1253
geoff.curtis@djescience.com

Source: Durata Therapeutics, Inc.